AU2020270917B2 - Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione - Google Patents

Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Info

Publication number
AU2020270917B2
AU2020270917B2 AU2020270917A AU2020270917A AU2020270917B2 AU 2020270917 B2 AU2020270917 B2 AU 2020270917B2 AU 2020270917 A AU2020270917 A AU 2020270917A AU 2020270917 A AU2020270917 A AU 2020270917A AU 2020270917 B2 AU2020270917 B2 AU 2020270917B2
Authority
AU
Australia
Prior art keywords
compound
subject
rituximab
dlbcl
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020270917A
Other languages
English (en)
Other versions
AU2020270917A1 (en
Inventor
Maria Soraya Carrancio ANTON
Tonia J. Buchholz
Antonia Lopez-Girona
Rama Krishna Narla
Michael POURDEHNAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2020270917A1 publication Critical patent/AU2020270917A1/en
Application granted granted Critical
Publication of AU2020270917B2 publication Critical patent/AU2020270917B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020270917A 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione Active AU2020270917B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12
US62/833,432 2019-04-12
PCT/US2020/027358 WO2020210418A1 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (2)

Publication Number Publication Date
AU2020270917A1 AU2020270917A1 (en) 2021-11-04
AU2020270917B2 true AU2020270917B2 (en) 2025-08-28

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020270917A Active AU2020270917B2 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Country Status (27)

Country Link
US (3) US11390617B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7562557B2 (cg-RX-API-DMAC7.html)
KR (1) KR102944213B1 (cg-RX-API-DMAC7.html)
CN (1) CN114144182B (cg-RX-API-DMAC7.html)
AR (1) AR119715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020270917B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020372A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132538A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002651A1 (cg-RX-API-DMAC7.html)
DK (1) DK3952880T3 (cg-RX-API-DMAC7.html)
ES (1) ES3061998T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952880T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251668T1 (cg-RX-API-DMAC7.html)
IL (1) IL287145A (cg-RX-API-DMAC7.html)
LT (1) LT3952880T (cg-RX-API-DMAC7.html)
MA (1) MA55608A (cg-RX-API-DMAC7.html)
MX (1) MX428518B (cg-RX-API-DMAC7.html)
PL (1) PL3952880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952880T (cg-RX-API-DMAC7.html)
RS (1) RS67593B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111232RA (cg-RX-API-DMAC7.html)
SI (1) SI3952880T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI853014B (cg-RX-API-DMAC7.html)
WO (1) WO2020210418A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107668B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
AU2020369497C1 (en) * 2019-10-21 2026-05-07 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
IL292375A (en) 2019-10-21 2022-06-01 Celgene Corp Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use
AU2020372333B2 (en) * 2019-10-21 2026-08-06 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
HRP20231487T1 (hr) 2019-10-21 2024-03-01 Celgene Corporation Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona
CN114885602A (zh) * 2019-10-21 2022-08-09 新基公司 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法
IL307257A (en) * 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
US20240207281A1 (en) * 2021-04-21 2024-06-27 Celgene Corporation Methods of treating b-cell lymphoma using combination therapy
CN117241802A (zh) * 2021-04-21 2023-12-15 新基公司 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法
AU2022300184A1 (en) 2021-06-21 2023-11-16 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
WO2026099206A1 (en) 2024-11-05 2026-05-15 Celgene Corporation Therapy for the treatment of non-hodgkin lymphoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US8648096B2 (en) * 2006-09-15 2014-02-11 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) * 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US20150297579A1 (en) 2012-11-05 2015-10-22 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject
EP2981262A1 (en) * 2013-04-02 2016-02-10 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Also Published As

Publication number Publication date
RS67593B1 (sr) 2026-01-30
EP3952880A1 (en) 2022-02-16
IL287145A (en) 2021-12-01
SMT202600013T1 (it) 2026-03-09
US11390617B2 (en) 2022-07-19
PL3952880T3 (pl) 2026-05-18
MX428518B (es) 2025-11-13
BR112021020372A2 (pt) 2021-12-07
JP2022527398A (ja) 2022-06-01
US20200325129A1 (en) 2020-10-15
AU2020270917A1 (en) 2021-11-04
TWI853014B (zh) 2024-08-21
DK3952880T3 (da) 2026-01-26
WO2020210418A1 (en) 2020-10-15
EP3952880B1 (en) 2025-12-10
US20240400548A1 (en) 2024-12-05
ES3061998T3 (en) 2026-04-08
HRP20251668T1 (hr) 2026-02-27
US20220324855A1 (en) 2022-10-13
KR20210151895A (ko) 2021-12-14
ZA202107668B (en) 2025-01-29
MX2021012507A (es) 2022-01-24
LT3952880T (lt) 2026-01-26
MA55608A (fr) 2022-02-16
US12103923B2 (en) 2024-10-01
SI3952880T1 (sl) 2026-02-27
JP7562557B2 (ja) 2024-10-07
FI3952880T3 (fi) 2026-02-05
AR119715A1 (es) 2022-01-05
CA3132538A1 (en) 2020-10-15
TW202103705A (zh) 2021-02-01
KR102944213B1 (ko) 2026-03-26
CN114144182A (zh) 2022-03-04
CL2021002651A1 (es) 2022-04-29
SG11202111232RA (en) 2021-11-29
PT3952880T (pt) 2026-02-17
CN114144182B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
US12103923B2 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
AU2020369497C1 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
CN107073122A (zh) 恶性肿瘤的联合治疗
EP4048278A1 (en) Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
EA047955B1 (ru) Способы лечения неходжкинской лимфомы с использованием 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
US20250017941A1 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)